Summary
This report is the companion to the publisher’s Gene Therapy Market Opportunity for CMOs - 2019 Edition and Cell Therapy Market Opportunity for CMOs - 2018 Edition reports, which described the demand and supply for contract manufacturing in the gene and cell therapy markets. This latest report examines the approvals and manufacturing outlook for three drug molecule types that all require viral vectors in their production: gene therapies, gene-modified cell therapies, and recombinant vector vaccines. The report is critical for benchmarking the CMO industry's capacity to manufacture these vital vaccines and drugs and forecasting future approvals.
Scope
This 62-page report gives important, expert insight you won’t find in any other source. 22 figures and 15 tables throughout the report illustrate major points and trends. This report is required reading for -
Reasons to Buy
This report is the companion to the publisher’s Gene Therapy Market Opportunity for CMOs - 2019 Edition and Cell Therapy Market Opportunity for CMOs - 2018 Edition reports, which described the demand and supply for contract manufacturing in the gene and cell therapy markets. This latest report examines the approvals and manufacturing outlook for three drug molecule types that all require viral vectors in their production: gene therapies, gene-modified cell therapies, and recombinant vector vaccines. The report is critical for benchmarking the CMO industry's capacity to manufacture these vital vaccines and drugs and forecasting future approvals.
Scope
This 62-page report gives important, expert insight you won’t find in any other source. 22 figures and 15 tables throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the vaccine, cell therapy, and gene therapy marketplace to make strategic planning and investment decisions about viral vector manufacturing.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private Equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
- Detailed view of the geographic distribution of viral vector contract manufacturing facilities worldwide and the proportion belonging to dedicated CMOs and excess capacity manufacturers
- Leader and disruptor companies in the viral vector space
- Analysis of pipeline and marketed gene therapies, cell therapies, and recombinant vector vaccines, by geography, development stage, and clinical trials
- A detailed model forecasting future gene therapy, cell therapy, and recombinant vector vaccine approvals, and associated manufacturing volumes
- Contract manufacturing agreements for the active pharmaceutical ingredient (API) component of these vaccines and therapies
Table of Contents
1 Executive Summary2 Players4 Trends8 Companies
3 Technology Briefing
5 Industry Analysis
6 Approvals and Volume Model
7 Value Chain - Contract Manufacturing Capabilities
9 Appendix
10 About the Authors
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics Inc
- Abeona Therapeutics Inc
- ActogeniX NV
- Adaptimmune Ltd
- Adrenas Therapeutics Inc Aspa Therapeutics Inc BridgeBio Pharma Inc
- Advanced BioScience Laboratories Inc
- Advantagene Inc
- Advaxis Inc
- Advent Srl
- AGC Biologics SpA
- Ajinomoto Bio-Pharma Services
- Albany Molecular Research Inc
- Albert B. Sabin Vaccine Institute Inc
- Aldevron LLC
- Almac Group Ltd
- Altimmune Inc
- Amicus Therapeutics Inc
- Anchiano Therapeutics Ltd
- Aruvant Sciences Inc
- ASC Therapeutics Inc
- Aslan Pharmaceuticals Ltd
- Aspen Pharmacare Holdings Ltd
- AstraZeneca KK
- AstraZeneca Plc
- AstraZeneca Plc University of Oxford
- Attwill Medical Solutions
- Batavia Biosciences BV
- Baxter Biopharma Solutions
- Benitec Biopharma Inc
- BioCell Corp Ltd
- Biological E Ltd
- BioReliance Corp
- bluebird bio Inc
- Boehringer Ingelheim Biopharmaceuticals GmbH Boehringer Ingelheim RCV GmbH & Co KG
- BriaCell Therapeutics Corp
- Caladrius Biosciences Inc
- Candel Therapeutics
- Catalent Inc
- Cell and Gene Therapy Catapult
- Cell Therapies Pty Ltd
- Cellectis SA
- CELLforCURE
- Celsion Corp
- Centaur Biopharmaceutical Services Inc
- Centre C3i
- Chinook Therapeutics Inc
- City of Hope
- Coalition for Epidemic Preparedness Innovations Public Health Vaccines LLC
- Cobra Biologics Ltd
- CombiGene AB
- Corautus Genetics Inc. (Inactive)
- CRISPR Therapeutics AG
- Daiichi Sankyo Biotech Co Ltd
- Decibel Therapeutics Inc
- DiNAQOR AG
- Dompe Farmaceutici SpA
- Editas Medicine Inc
- Eiger BioPharmaceuticals Inc
- ElevateBio LLC
- Emergent BioSolutions Inc
- enGene Inc
- Flexion Therapeutics Inc
- Forte Biosciences Inc
- Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV
- Freeline Therapeutics Holdings Plc
- Fujifilm Diosynth Biotechnologies USA Inc
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- Genethon SA Sarepta Therapeutics Inc
- Genprex Inc
- Genscript Biotech Corp
- GenVec LLC
- GeoVax Labs Inc
- German Center for Infection Research
- GlaxoSmithKline Plc
- Grand River Aseptic Manufacturing Inc
- Halix BV
- Handl Therapeutics BV
- Helocyte Biosciences Inc
- Helocyte, Inc.
- Hookipa Pharma Inc
- IDT Biologika GmbH
- IN8bio Inc
- Indapta Therapeutics Inc
- Innobation Co Ltd
- Insud Pharma
- International AIDS Vaccine Initiative
- Ion Channel Innovations LLC
- iosBio Pharma Ltd
- Iovance Biotherapeutics Inc
- IVERIC bio Inc
- Janssen Pharmaceutica NV
- Janssen Pharmaceutica NV Janssen Pharmaceuticals Inc
- Janssen Pharmaceuticals Inc
- JCR Pharmaceuticals Co Ltd
- Jenner Institute
- Johnson & Johnson
- Juventas Therapeutics Inc
- KBI Biopharma Inc
- Kite Pharma Inc
- Laboratorio Reig Jofre SA
- Lentigen Technology Inc
- Les Laboratoires Servier SAS
- Lonza Group Ltd
- Lysogene SAS
- Massachusetts General Hospital
- MaSTherCell SA
- MaxCyte Inc
- Merck KGaA
- MilliporeSigma
- Minaris Regenerative Medicine GmbH
- Minaris Regenerative Medicine LLC
- Minaris Regenerative Medicine LLC Showa Denko Materials Co Ltd
- MTG Biotherapeutics Inc
- Mustang Bio Inc
- Noga Therapeutics Ltd
- Novartis AG
- Novartis Gene Therapies
- Novartis International AG
- Novasep Holding SAS
- Novavax Inc
- Ology Bioservices Inc
- OncoSec Medical Inc
- Oncternal Therapeutics
- Orchard Therapeutics Plc
- Otsuka Holdings Co Ltd
- Oxford BioMedica Plc
- Oxford-Emergent Tuberculosis Consortium Limited (Inactive)
- Passage Bio Inc
- Patheon NV
- Patheon NV Patheon Viral Vector Services
- Pfizer Inc
- Pharmasyntez
- Poseida Therapeutics Inc
- Prevail Therapeutics Inc
- ProBioGen AG
- Profectus BioSciences Inc
- Provecs Medical GmbH
- PTC Therapeutics Inc
- Rega Institute for Medical Research
- RegenxBio Inc
- ReiThera Srl
- Renova Therapeutics Inc
- Richter-Helm BioLogics GmbH & Co KG
- Rocket Pharmaceuticals Inc
- SanBio Company Limited
- Sangamo Therapeutics France SAS
- Sanofi
- Sarepta Therapeutics Inc
- Scenic Biotech BV
- Selecta Biosciences Inc
- Selexis SA
- Sensorion SA
- SGS Life Science Services
- Sio Gene Therapies Inc
- SK Bioscience
- Spark Therapeutics Inc
- Symbiosis Pharmaceutical Services Ltd
- Synlogic Inc
- Takara Bio Inc
- Taysha Gene Therapies
- TCR2 Therapeutics Inc
- Themis Bioscience GmbH
- T-Knife GmbH
- Tonix Pharmaceuticals Holding Corp
- Triumvira Immunologics Inc
- TTY Biopharm Co Ltd
- Ultragenyx Pharmaceutical Inc
- UniQure NV
- University of Oxford
- Valneva SE
- Vaxart Inc
- VGXI Inc
- Vibalogics GmbH
- Vigene Biosciences Inc
- ViGeneron GmbH
- Vir Biotechnology Inc
- Viralgen
- Vivebiotech SL
- Vivet Therapeutics SAS
- Wacker Chemie AG
- Waisman Biomanufacturing
- WuXi AppTec (Shanghai) Co Ltd
- WuXi AppTec Co Ltd
- Xyphos Biosciences Inc
- Yposkesi SAS
- Zhejiang Hisun Pharmaceutical Co Ltd
- ZIOPHARM Oncology Inc